Skip to main content
SpringerLink
Log in

An Overview of the Diagnosis and Treatment of Erectile Dysfunction

  • Therapy In Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Quality-of-life issues are now a matter of great importance to the aging population. Men and their partners are no longer prepared to merely accept ED as a natural consequence of aging. The advent of a simple and effective oral therapy for ED has also indirectly fuelled the increase in treatment-seeking behaviour among men.

Despite great strides in research into ED, our knowledge and understanding of the pathophysiological mechanisms is still in its infancy. As a result, we are able to treat only the symptom of ED rather than prevent it. Common diseases found in the population, such as diabetes mellitus and coronary artery disease appear to be risk factors for the development of ED. Therefore, physicians need to identify any underlying co-existing organic diseases in their patients presenting with ED.

Whenever possible, patients are encouraged to attend their consultation sessions with their partners because ED is a condition affecting ‘the couple’ and not just the man. Psychogenic aspects of ED should also be explored during the consultation. Efforts need to be made to uncover and address the presence of any psychological stressors, if necessary with the help of a psychosexual therapist.

The first-line treatment of ED is oral phosphodiesterase-5 inhibitors. For those who do not respond to oral therapy, there is no defined ‘step-ladder’ escalation in alternative therapy. It is up to the physician to discuss the options with the patient or couple and reach a decision based on their preference.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Table IV
Table V
Table VI
Table VII
Table VIII
Table IX

Similar content being viewed by others

References

  1. The Second International Consultation on Dysfunction. Sexual Medicine: Sexual Dysfunctions in Men and Women. 2004 Jun 28-Jul 1; Paris

  2. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudal results from the Massachusetts Male Aging Study. J Urol 2000; 163: 460–3

    Article  PubMed  CAS  Google Scholar 

  3. Moreira Jr ED, Lbo CF, Diament A, et al. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology 2003; 61: 431–6

    Article  PubMed  Google Scholar 

  4. Schouten BW, Bosch JL, Bernsen RM, et al. Incidence of clinical relevant erectile dysfunction (ED) and ED by two other common definitions: strong effect of definition and bias by duration follow-up. Int J Impot Res 2005; 17: 58–62

    Article  PubMed  CAS  Google Scholar 

  5. Kinsey AC, Pomeroy WB, Martin CE. Sexual behaviour of the human male. Philadelphia (PA): WB Saunders and Co, 1948

    Google Scholar 

  6. Shabsig R, Alexandre A, Bay Nielsen H, et al. Economic aspects of erectile dysfunction [abstract]. 1st International Consultation on Erectile Dysfunction; 1999 Jul 1–3; Paris. Plymouth: Plymbridge Distributors Ltd

  7. Sexual Dysfunction Therapeutics. A market overview and therapeutics analysis 2002. San Mateo (CA): Frontline Strategic Consultation Inc., 2002

    Google Scholar 

  8. British National Formulary. No. 51 (Mar 2006). London: BMJ Publishing Group Ltd, 2006

  9. Lizza EF, Rosen RC. Definition and classification of erectile dysfunction: report of the Nomenclature Committee of the International Society of Impotence Research. Int J Imp Res 1999; 11: 141–4

    Article  CAS  Google Scholar 

  10. Wespes E, Amar E, Hatzichristou D, et al. Guidelines of erectile dysfunction: European Association of Urology 2006 [online]. Available from URL: http://www.uroweb.org/index.php?.structure_id=140. [Accessed 2006 Aug 24]

  11. Hengeveld MW. Erectile disorder: a psychosexological review. In: Jonas U, Thon WF, Stief CG, editors. Erectile dysfunction. Berlin: Springer Verlag, 1991

    Google Scholar 

  12. O’Leary MP, Fowler FJ, Lenderking WR, et al. A brief male sexual function inventory for urology. Urology 1995; 46: 782–3

    Google Scholar 

  13. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–30

    Article  PubMed  CAS  Google Scholar 

  14. Althof SE, Corty EW, Morales SB, et al. Development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999; 53: 793–9

    Article  PubMed  CAS  Google Scholar 

  15. Morley JE, Charlton E, Patrick P, et al. Validation of screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239–42

    Article  PubMed  CAS  Google Scholar 

  16. Heaton JP, Adams MA, Morales A. A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative. Int J Impot Res 1997; 9: 115–21

    Article  PubMed  CAS  Google Scholar 

  17. Ballard SA, Gingell JC, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum in vitro and on the activities of cyclic nucleotide phosphodiesterase isozyme. J Urol 1998; 159: 2164–71

    Article  PubMed  CAS  Google Scholar 

  18. Baxendale RW, Smith EJ, Stanley M, et al. Selectivity of sildenafil citrate and other phosphodiesterases type 5 inhibitors against phosphodiesterases types 7–11 [abstract]. J Clin Pharmacol 2001; 41: 1015

    Google Scholar 

  19. Saenz de Tejada I, Angula J, Cuevas P, et al. The phosphodiesterase inhibitor selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282–90

    Article  PubMed  CAS  Google Scholar 

  20. Giuliano F. Phosphodiesterase type 5 inhibition in erectile dysfunction: an overview. Eur Heart J 2002; 4 Suppl. H: H7–12

    CAS  Google Scholar 

  21. Viagra®: summary of product characteristics [online]. Available from URL: http://pfizer.com/download/uspi_viagra.pdf. [Accessed 2006 May 4]

  22. Cialis®: summary of product characteristics [online]. Available from URL: http://www.health.gov.il/units/pharmacy/trufot/alonim/1518.pdf [Accessed 2006 May 4]

  23. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. New Engl J Med 1998; 338: 1397–404

    Article  PubMed  CAS  Google Scholar 

  24. Langtry HD, Markham A. Sildenafil: a review of its use in erectile dysfunction. Drugs 1999; 57: 845–1039

    Article  Google Scholar 

  25. Zelefsky MJ, Mckee AB, Lee H, et al. Efficacy of sildenafil in patients with erectile dysfunction after radiotherapy of the prostate. Urology 1999; 53: 775–8

    Article  PubMed  CAS  Google Scholar 

  26. Merrick GS, Butler WM, Lief JH, et al. Efficacy of sildenafil in prostate brachytherapy patients with erectile dysfunction. Urology 1999; 53: 1112–6

    Article  PubMed  CAS  Google Scholar 

  27. Zippe CD, Jhaveri FM, Klein EA, et al. Role of Viagra after radical prostatectomy. Urology 2000; 55: 241–5

    Article  PubMed  CAS  Google Scholar 

  28. Sadovsky R, Miller T, Moskowitz M, et al. Three year update of sildenafil citrate (Viagra™) efficacy and safety. Int J Clin Prac 2001; 55: 115–28

    CAS  Google Scholar 

  29. Morales A, Gingell GC, Collins M, et al. Clinical safety of oral sildenafil citrate in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69–73

    Article  PubMed  CAS  Google Scholar 

  30. Arruda Olson A, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. JAMA 2002 287: 719–25

    Article  PubMed  CAS  Google Scholar 

  31. Hermann HC, Chang G, Klugherz BD, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. New Engl J Med 2000; 342: 1622–6

    Article  Google Scholar 

  32. Fazio L, Brock G. Erectile dysfunction: management update. CMAJ 2004; 170: 1429–37

    Article  PubMed  Google Scholar 

  33. Hellstrom WG, Gittleman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized double-blind placebo controlled trial. J Androl 2002; 23: 763–72

    PubMed  CAS  Google Scholar 

  34. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new highly selective PDE5 inhibitor improves erectile function in patients with diabetes mellitus. Proc Am Diabetic Assoc Jun 2001

  35. Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170: 1278–83

    Article  PubMed  CAS  Google Scholar 

  36. Levitra®: summary of product characteristics [online]. Available from URL: http://www.levitra.co.uk/smpc.htm. [Accessed 2006 May 4]

  37. Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent highly selective phosphodiesterase inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardio 2002; 40: 2006–12

    Article  CAS  Google Scholar 

  38. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1322–6

    Article  Google Scholar 

  39. Porst H, Padma-Nathan H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomised controlled trial. Urology 2003; 62: 121–5

    Article  PubMed  Google Scholar 

  40. Stark S, Sachse R, Liedl T, et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001; 40: 181–8

    Article  PubMed  CAS  Google Scholar 

  41. Klotz T, Sachse R, Heidrich A, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a Rigiscan and pharmacokinetic study. World J Urol 2001; 19: 32–9

    Article  PubMed  CAS  Google Scholar 

  42. Hellstrom WJ, Overstreet JW, Yu A, et al. Tadalafil has no deleterious effect on spermatogenesis or reproductive hormones. J Urol 2003; 170: 887–91

    Article  PubMed  CAS  Google Scholar 

  43. Saenz de Tejada I, Anglin G, Knight JR, et al. Effects of tadalafil on erectile function in men with diabetes. Diabetes Care 2002; 25: 2159–64

    Article  PubMed  Google Scholar 

  44. Patterson D, Kloner R, Effron MB, et al. The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. Br J Clin Pharmacol 2005; 60: 459–68

    Article  PubMed  CAS  Google Scholar 

  45. Stroberg P, Yu CC, Su CC, et al. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 2003; 25: 2724–37

    Article  PubMed  Google Scholar 

  46. von Keitz A, Rajfer J, Segal S, et al. A multicenter, randomised, double-blind, cross-over study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499–507

    Article  Google Scholar 

  47. Govier F, Potempa AJ, Kaufman J, et al. A multicenter, randomised, double blind, cross-over study of patient preference for tadalafil 20mg or sildenafil citrate 50mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25: 2709–23

    Article  PubMed  CAS  Google Scholar 

  48. Mulhall JP, Montorsi F. Evaluating preference trials of oral phosphodiesterase 5 inhibitor for erectile dysfunction. Eur Urol 2006; 49: 30–7

    Article  PubMed  CAS  Google Scholar 

  49. Eardley I, Mirone V, Montorsi F, et al. An open label, multicentre, randomised, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323–32

    Article  PubMed  CAS  Google Scholar 

  50. Dula E, Bukofzer S, Perdol R, et al. Double blind, crossover comparison of 3mg apomorphine SL with placebo and with 4mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558–64

    Article  PubMed  CAS  Google Scholar 

  51. Heaton JP. Key issues from clinical trial of apomorphine SL. Int J Impot Res 2000; Suppl. 4: S67–73

    Google Scholar 

  52. Eardley I, Wright P, Macdonagh R, et al. An open label, randomised, flexible dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004; 93: 1271–5

    Article  PubMed  CAS  Google Scholar 

  53. Shabsigh R, Padma-Natham H, Gittleman M, et al. Intracavernous alprostadil alfadex (Edex/Viridal) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 2000; 55: 274–9

    Google Scholar 

  54. Junemann KP, Manning M, Krautschik A, et al. 15 years of injection therapy in erectile dysfunction: a review [abstract]. Int J Impot Res 1996; 8: A60

    Google Scholar 

  55. Dinsmore WW, Gingell C, Hackett G, et al. Treating men with predominantly, nonpsychogenic erectile dysfunction with vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo controlled study. BJU Int 1999; 83: 274–9

    Article  PubMed  CAS  Google Scholar 

  56. VIVIUS Inc. MUSE® summary of product characteristics [online]. Available from URL: http://www.muserx.net/res/pack_inserts_PFI_1.3pdf [Accessed 2006 Nov 21]

  57. Padma-Nathan H, Hellstrom W, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. New Eng J Med 1997; 336: 1–7

    Article  PubMed  CAS  Google Scholar 

  58. Williams G, Abbou CC, Amar ET, et al. The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction and their partners. Br J Urol 1998; 82: 847–54

    Article  PubMed  Google Scholar 

  59. Shabsigh R, Padma-Natham H, Gittleman M, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomised, crossover multicentre study. Urology 2000; 55: 109–13

    Article  PubMed  CAS  Google Scholar 

  60. Gauthier A, Rutchik DS, Winters CJ, et al. Relative efficacy of sildenafil compared to other treatment options for erectile dysfunction. South Med J 2000; 93: 962–5

    PubMed  CAS  Google Scholar 

  61. Meyhoff H, Rosenkilde P, Bodker A. Non-invasive management of impotence with transcutaneous nitrogylcerine. Br J Urol 1992; 69: 88–90

    Article  PubMed  CAS  Google Scholar 

  62. Goldstein I, Payton TR, Schecter PJ. A double blind, placebo controlled, efficacy and safety study of topical gel formulation of 1 % alprostadil (Topiglan™) for in-office treatment of erectile dysfunction. Urology 2001; 57: 301–4

    Article  PubMed  CAS  Google Scholar 

  63. Gomaa A, Shalaby M, Osman M, et al. Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate and co-dergocrine mesylate. BMJ 1996; 312: 1512–5

    Article  PubMed  CAS  Google Scholar 

  64. Buvat J, Lemaire A. Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158: 1764–7

    Article  PubMed  CAS  Google Scholar 

  65. Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endcrinol Metab 1990; 71: 963–9

    Article  CAS  Google Scholar 

  66. Tenover JL. Testosterone replacement therapy in older men. Int J Androl 1999; 22: 300–6

    Article  PubMed  CAS  Google Scholar 

  67. Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia 2006; 38: 61–8

    Article  PubMed  CAS  Google Scholar 

  68. Rosenthal BD, May NR, Metro MJ, et al. Adjuvant use of Androgel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006; 67: 571–4

    Article  PubMed  Google Scholar 

  69. Shamloul R, Ghanem H, Fahmy I, et al. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med 2005; 4: 559–4

    Article  Google Scholar 

  70. Shabsigh R, Kaufman JM, Steidle C, et al. Randomised study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658–63

    Article  PubMed  CAS  Google Scholar 

  71. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients. Endocr Pract 2002; 8: 439-56

    Google Scholar 

  72. Cookson MS, Nadig PW. Long-term results with vacuum constriction devices. J Urol 1993; 149: 290–4

    PubMed  CAS  Google Scholar 

  73. Gilbert HW, Gingell JC. Vacuum constriction devices: second-line conservative treatment for impotence. Br J Urol 1992; 70: 81–3

    Article  PubMed  CAS  Google Scholar 

  74. Levine LA, Estrada CR, Morgentaler A. Mechanical reliability and safety of and patient satisfaction with Ambicor inflatable penile prosthesis: results of a two center study. J Urol 2001; 166: 932–7

    Article  PubMed  CAS  Google Scholar 

  75. Montorsi F, Rigatti P, Carmignani G, et al. AMS three piece inflatable implants for erectile dysfunction: a long-term multiinstitutional trial studying 200 consecutive patients. Eur Urol 2000; 35: 50–5

    Article  Google Scholar 

  76. Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700 CX inflatable penile prosthesis: results of long-term multi-center study. J Urol 2000; 164: 376–80

    Article  PubMed  CAS  Google Scholar 

  77. Montague DK, Angermeier KW, Lakin MM. Penile prosthesis infections. Int J Impot Res 2001; 13: 326–8

    Article  PubMed  CAS  Google Scholar 

  78. Wilson SK, Delk JR, Henry GD. Short term follow for enhanced American Medical Systems 700 CX prosthesis [abstract no. 600A]. J Urol 2002; 167 Suppl. 4

  79. Wolter CE, Hellstrom WJ. The hydrophilic coated inflatable penile prosthesis: 1 year experience. J Sex Med 2004; 1: 221–4

    Article  PubMed  Google Scholar 

  80. Mulcahy JJ. Long-term experience with salvage of infected penile prosthesis. J Urol 2000; 163: 481–2

    Article  PubMed  CAS  Google Scholar 

  81. Fishman IJ, Scott FB, Selim A, et al. The rescue procedure: an alternative for managing infected penile prosthesis. Contemp Urol 1997; 11: 73–80

    Google Scholar 

  82. Kaufman JM, Kaufman JL, Borges FD. Immediate salvage procedure for infected penile prosthesis. J Urol 1998; 159: 816–9

    Article  PubMed  CAS  Google Scholar 

  83. Sharaby JS, Benet AE, Melman A. Revascularisation: a five year follow-up study [abstract]. J Urol 1995; 153: 369A

    Google Scholar 

  84. Konnak JW, Ohl DA. Microsurgical penile revascularisation using central corporeal penile artery. J Urol 1989; 142: 305–8

    PubMed  CAS  Google Scholar 

  85. Depalma RG. Vascular surgery for impotence: a review. Int J Impot Res 1997; 9: 61–7

    Article  PubMed  CAS  Google Scholar 

  86. Rao DS, Donatucci CF. Vasculogenic impotence: arterial and venous surgery. Urol Clin NA 2001; 22: 309–19

    Article  Google Scholar 

  87. Berradinucci C, Morales A, Heaton JP, et al. Surgical treatment of penile veno-occlusive dysfunction: is it justified? Urology 1997; 47: 88–92

    Article  Google Scholar 

  88. Schultheiss D, Truss MC, Becker AJ, et al. Long-term results following dorsal penile ligation in 126 patients with veno-occlusive dysfunction. Int J Impot Res 1997; 9: 205–9

    Article  PubMed  CAS  Google Scholar 

  89. Lukkarinen O, Tontilla P, Hellstrom P, et al. Non prosthetic surgery in the treatment of erectile dysfunction. Scan J Urol Nephrol 1997; 32: 42–6

    Google Scholar 

  90. Arjona M, Osteros R, Zarca M, et al. Percutaneous embolisation for erectile dysfunction due to venous leakage: prognostic factors for good therapeutic results. Eur Urol 2001; 39: 15–9

    Google Scholar 

  91. Miwa Y, Shioyama R, Itou Y, et al. Pelvic venoablation with ethanol for the treatment of erectile dysfunction due to veno-occlusive dysfunction. Urology 2001; 58: 76–9

    Article  PubMed  CAS  Google Scholar 

  92. Peskircioglu L, Tekin I, Boyvat F, et al. Embolisation of the deep dorsal vein for the treatment of erectile impotence due to veno-occlusive dysfunction. J Urol 2000; 163: 472–5

    Article  PubMed  CAS  Google Scholar 

  93. Alossini G, Ficarra V, Cavalleri S, et al. Long-term results of veno-occlusive percutaneous treatment of erectile disorders of venous origin. Arch Ital Androl 1998; 70: 203–9

    Google Scholar 

  94. Martinez Portillo FJ, Junemann KP, Sohn M. Surgical therapy of erectile dysfunction: current status [in German]. Urologe A 2003; 42: 1337–44

    Article  PubMed  CAS  Google Scholar 

  95. Dorey G, Speakman MJ, Feneley RCL, et al. Pelvic floor exercises for erectile dysfunction. BJU Int 2005; 96: 595–7

    Article  PubMed  Google Scholar 

  96. Masters WH, Johnson VE. Human sexual inadequacy. London: Churchill, 1970

    Google Scholar 

  97. Hawton K, Catalan J. Prognostic factors in sex therapy. Behav Sex Ther 1986; 24: 377–85

    CAS  Google Scholar 

  98. Barnes P. Role of sex therapy in the management of ED. In: Kirby RS, Carson C, Webster GD, editors. Impotence diagnosis and management of male ED. Oxford: Butterworth-Heinemann, 1991

    Google Scholar 

Download references

Acknowledgements

Dr Schwaibold is, or has been, an investigator and consultant for pharmaceutical companies producing and developing drugs for erectile dysfunction. The companies to which Dr Schwaibold has affiliations include Bayer, Lilly, Icos and Pfizer. Dr Sivalingam and Dr Hashim have no potential conflicts of interest to declare. No sources of funding were used to assist in the preparation of this review.

Author information

Authors and Affiliations

  1. Bristol Urological Institute, Southmead Hospital, Westbury-on-Trym, Bristol, UK

    Sivaprakasam Sivalingam, Hashim Hashim & Hartwig Schwaibold

Authors
  1. Sivaprakasam Sivalingam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hashim Hashim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hartwig Schwaibold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sivaprakasam Sivalingam.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sivalingam, S., Hashim, H. & Schwaibold, H. An Overview of the Diagnosis and Treatment of Erectile Dysfunction. Drugs 66, 2339–2355 (2006). https://doi.org/10.2165/00003495-200666180-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666180-00006

Keywords

Search

Navigation